admin – Page 2444 – Get News Story

Acoustic Neuroma Market Outlook 2034 – Clinical Trials, Market Size, Medication, Prevalence, Companies by DelveInsight

“Acoustic Neuroma Market”

Acoustic Neuroma companies are Akouos, Amgen, Roche, Natus Medical Incorporated, Elekta, Pfizer Inc., Roche AG, CIVCO MEDICAL SOLUTIONS, Novartis AG, MAICO Diagnostics GmbH, Siemens Healthcare GmbH, Interacoustics A/S, Natus Medical Incorporated, and others.

(Albany, USA) DelveInsight’s report, “Acoustic Neuroma Market Insights, Epidemiology, and Market Forecast–2034”, offers a comprehensive analysis of Acoustic Neuroma, including historical and projected epidemiology, along with market trends across the United States, the EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

The report details current treatment practices, emerging therapies, market share by individual treatments, and the Acoustic Neuroma market size from 2020 to 2034, segmented across the seven major markets. It further outlines the existing treatment algorithms, key market drivers and barriers, as well as unmet medical needs—identifying the best growth opportunities and evaluating the market’s overall potential.

Request for a Free Sample Report @ Acoustic Neuroma Market Forecast

Some facts of the Acoustic Neuroma Market Report are:

According to DelveInsight, Acoustic Neuroma market size is expected to grow at a decent CAGR by 2034.
Leading Acoustic Neuroma companies working in the market are Akouos, Amgen, Roche, Natus Medical Incorporated, Elekta, Pfizer Inc., Roche AG, CIVCO MEDICAL SOLUTIONS, Novartis AG, MAICO Diagnostics GmbH, Siemens Healthcare GmbH, Interacoustics A/S, Natus Medical Incorporated, and others.
Key Acoustic Neuroma Therapies expected to launch in the market are AK-antiVEGF, and many others.
In August 2025, Akouos, Inc announced results of a Phase 1/2 Trial of AAVAnc80-antiVEGF Gene Therapy in Individuals With Unilateral Vestibular Schwannoma
In April 2025, Reveal Pharmaceuticals Inc announced results of a Multi-Center, Phase 2, Open Label, Ascending Dose Study to Evaluate the Safety and Efficacy of RVP-001 and to Identify an Appropriate Dose to Detect CNS Lesions in Adult Patients
According to our finding, the overall incidence of vestibular schwannoma is approximately 3 to 5 per 100,000 person-years. The incidence rises with advancing age. For patients over 70 years of age, the incidence may be as high as 21 per 100,000 person-years.
As per Greene J et al. (2024), Schwannomas account for approximately 8% of all clinically manifested intracranial tumors. However, genetic factors contribute to developing bilateral acoustic neuromas, constituting less than 5% of all schwannomas.

Acoustic Neuroma Overview

Acoustic neuroma, also known as vestibular schwannoma, is a rare, typically benign tumor that develops from the Schwann cells covering the vestibulocochlear nerve (cranial nerve VIII), which is responsible for hearing and balance. These tumors grow slowly and are usually located between the inner ear and the brain. The condition often presents with unilateral or asymmetric hearing loss, tinnitus (ringing in the ear), dizziness, and balance disturbances. As the tumor enlarges, it can compress adjacent cranial nerves, including the trigeminal nerve, leading to facial numbness or tingling, and in severe cases, affect brainstem function.

The incidence of acoustic neuroma is estimated at 3–5 cases per 100,000 person-years, with higher prevalence among older adults, especially those over 70 years. While most cases occur sporadically, some are associated with neurofibromatosis type 2 (NF2), a genetic disorder that causes multiple tumors of the nervous system. Diagnosis is typically made through magnetic resonance imaging (MRI).

Current management strategies include active surveillance, microsurgical removal, and stereotactic radiosurgery, depending on tumor size, growth rate, symptoms, and patient health. There are currently no FDA-approved drugs for acoustic neuroma, though off-label treatments like bevacizumab show promise in selected cases, highlighting an unmet need for targeted medical therapies.

Do you know what will be the Acoustic Neuroma market share in 7MM by 2034 @ Acoustic Neuroma Treatment Market

Acoustic Neuroma Market Outlook

Between 2025 and 2034, the acoustic neuroma market is projected to grow steadily, fueled by improved diagnostics, increased awareness, and advances in treatments such as stereotactic radiosurgery, microsurgical techniques, and targeted therapies.

The aging population and higher prevalence of NF2-associated tumors are expanding the patient base. Novel drug candidates, notably Akouos’s AK-antiVEGF, aim to control tumor growth and preserve hearing, though no FDA-approved therapies currently exist for this condition. Present treatments—surgery, radiotherapy, and active surveillance—carry notable risks, highlighting the urgent need for safer, nerve-preserving options. Off-label use of agents like bevacizumab, lapatinib, and everolimus has shown promise, particularly in NF2 patients.

Acoustic neuroma typically causes hearing loss, tinnitus, dizziness, and facial numbness, with incidence increasing with age. Despite its benign nature, the tumor can cause debilitating symptoms. The current limited pipeline emphasizes a significant unmet need, but ongoing innovations suggest a potentially transformative decade ahead for acoustic neuroma management.

The acoustic neuroma market is driven by advancements in diagnostic imaging, increasing disease awareness, and improved treatment modalities such as stereotactic radiosurgery, microsurgical techniques, and targeted therapies. The rising prevalence of neurofibromatosis type 2 (NF2)-associated tumors, coupled with an aging global population, is expanding the patient pool. Additionally, the development of novel drug candidates like Akouos’s AK-antiVEGF, aimed at tumor control and hearing preservation, reflects growing research interest in addressing unmet needs.

However, market growth faces significant barriers, including the absence of FDA-approved drugs specifically for acoustic neuroma, a limited drug development pipeline, and the high risks associated with current treatment options such as surgery and radiotherapy. The rarity of the disease also limits large-scale clinical trials, slowing therapeutic innovation. Moreover, the benign nature of the tumor and the availability of active surveillance as a management strategy can reduce demand for aggressive interventions, creating further challenges in market expansion.

Acoustic Neuroma Epidemiology

The Acoustic Neuroma epidemiology section provides insights into the historical and current Acoustic Neuroma patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Acoustic Neuroma market report also provides the diagnosed patient pool, trends, and assumptions.

Segmented by:

Total incident Cases of acoustic neuroma
Total Diagnosed incident Cases of acoustic neuroma
Age-specific Cases of acoustic neuroma
Gender-specific Cases of acoustic neuroma

Some of the facts:

Acoustic neuromas are estimated to affect about 1 in 100,000 people in the general population.
Acoustic neuromas affect women more often than men. Most cases of acoustic neuroma develop in individuals between the ages of 30 and 60. Although quite rare, they can develop in children.

Interested to know how the emerging diagnostic approaches will be contributing in increased Acoustic Neuroma diagnosed prevalence pool? Download report @ Acoustic Neuroma Prevalence

Acoustic Neuroma Drugs Uptake

This section focuses on the uptake rate of the potential Acoustic Neuroma drugs recently launched in the Acoustic Neuroma market or expected to be launched in 2020-2034. The analysis covers the Acoustic Neuroma market uptake by drugs, patient uptake by therapies, and sales of each drug.

Acoustic Neuroma Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Acoustic Neuroma market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Acoustic Neuroma Pipeline Development Activities

The Acoustic Neuroma report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Acoustic Neuroma companies involved in developing targeted therapeutics.

Download report to know which TOP 3 therapies will be capturing the largest Acoustic Neuroma market share by 2034? Click here @ Acoustic Neuroma Medication and Drugs

Acoustic Neuroma Therapeutics Assessment

Major key companies are working proactively in the Acoustic Neuroma Therapeutics market to develop novel therapies which will drive the Acoustic Neuroma treatment markets in the upcoming years are Akouos, Amgen, Roche, Natus Medical Incorporated, Elekta, Pfizer Inc., Roche AG, CIVCO MEDICAL SOLUTIONS, Novartis AG, MAICO Diagnostics GmbH, Siemens Healthcare GmbH, Interacoustics A/S, Natus Medical Incorporated, and others.

Do you know how emerging drug launch will be impacting the Acoustic Neuroma market CAGR? Download sample report @ Acoustic Neuroma Clinical Trials and FDA Approvals

Acoustic Neuroma Report Key Insights

1. Acoustic Neuroma Patient Population

2. Acoustic Neuroma Market Size and Trends

3. Key Cross Competition in the Acoustic Neuroma Market

4. Acoustic Neuroma Market Dynamics (Key Drivers and Barriers)

5. Acoustic Neuroma Market Opportunities

6. Acoustic Neuroma Therapeutic Approaches

7. Acoustic Neuroma Pipeline Analysis

8. Acoustic Neuroma Current Treatment Practices/Algorithm

9. Impact of Emerging Therapies on the Acoustic Neuroma Market

Table of Contents

1. Key Insights

2. Executive Summary

3. Acoustic Neuroma Competitive Intelligence Analysis

4. Acoustic Neuroma Market Overview at a Glance

5. Acoustic Neuroma Disease Background and Overview

6. Acoustic Neuroma Patient Journey

7. Acoustic Neuroma Epidemiology and Patient Population

8. Acoustic Neuroma Treatment Algorithm, Current Treatment, and Medical Practices

9. Acoustic Neuroma Unmet Needs

10. Key Endpoints of Acoustic Neuroma Treatment

11. Acoustic Neuroma Marketed Products

12. Acoustic Neuroma Emerging Therapies

13. Acoustic Neuroma Seven Major Market Analysis

14. Attribute Analysis

15. Acoustic Neuroma Market Outlook (7 major markets)

16. Acoustic Neuroma Access and Reimbursement Overview

17. KOL Views on the Acoustic Neuroma Market

18. Acoustic Neuroma Market Drivers

19. Acoustic Neuroma Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/competitive-intelligence-services

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Acoustic Neuroma Market Outlook 2034 – Clinical Trials, Market Size, Medication, Prevalence, Companies by DelveInsight

Tendonitis Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis | Seikagaku Corporation, MetrioPharm, MiMedx, Zhejia

“Tendonitis Pipeline Analysis”

DelveInsight’s, “Tendonitis Pipeline Insight 2024” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Tendonitis pipeline landscape. It covers the Tendonitis pipeline drug profiles, including Tendonitis clinical trials and nonclinical stage products. It also covers the Tendonitis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

DelveInsight reports that more than four key companies are actively engaged in developing over four treatment therapies for Tendonitis.

Tendonitis Overview:

Tendonitis, also called tendinopathy, is the inflammation of a tendon — the tough connective tissue that links muscles to bones. It often develops due to injury, trauma, or repetitive joint movements. Based on the affected area, it may be referred to by specific names such as Achilles tendonitis or tennis elbow.

The condition commonly impacts the elbows, heels, shoulders, and wrists. Standard treatment includes rest, pain-relief medications, and anti-inflammatory drugs, while physical therapy helps strengthen muscles and support recovery. In more severe cases, surgical intervention may be necessary to repair the damaged tendon.

Request for a detailed insights report on Tendonitis pipeline insights @ https://www.delveinsight.com/report-store/tendonitis-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

“Tendonitis Pipeline Insight 2025” report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Tendonitis Therapeutics Market.

Key Takeaways from the Tendonitis Pipeline Report

DelveInsight’s Tendonitis pipeline report highlights a strong development landscape, with over four active companies working on more than four therapies for treating Tendonitis.
Key players in this space include Seikagaku Corporation, MetrioPharm, MiMedx, Zhejiang Xingyue Biotechnology Co., Ltd., R3 Stem Cell, Dobecure, Causeway Therapeutics, and others, all aiming to introduce innovative drugs to enhance treatment options.
Notable pipeline candidates currently in various stages of development include SI-613, MP1032, and others.
In addition, device-based innovations are emerging — for instance, TendoNova’s Ocelot, a handheld tool for mechanically fragmenting and debriding targeted tendon tissues, received FDA 510(k) clearance in May 2022 for commercial use in conditions such as tennis elbow and plantar fasciitis. Similarly, in May 2022, CoNextions Inc. secured FDA 510(k) clearance for a device designed to improve healing and functional outcomes in tendon repair surgeries.

Tendonitis Pipeline Analysis

The report provides insights into:

The report provides detailed insights into the key companies that are developing therapies in the Tendonitis Market.
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Tendonitis treatment.
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Tendonitis market.

Download our free sample page report on Tendonitis pipeline insights

Tendonitis Emerging Drugs

SI-613: Seikagaku Corporation
MP1032: MetrioPharm

Tendonitis Companies

Around four major companies are actively developing therapies for tendonitis, with Seikagaku Corporation having one of the most advanced drug candidates currently in Phase II clinical trials.

DelveInsight’s report covers around 4+ products under different phases of clinical development like

Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

Tendonitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intravenous
Subcutaneous
Oral
Intramuscular

Tendonitis Products have been categorized under various Molecule types such as

Monoclonal antibody
Small molecule
Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Tendonitis Therapies and Key Companies: Tendonitis Clinical Trials and advancements

Tendonitis Pipeline Therapeutic Assessment

• Tendonitis Assessment by Product Type

• Tendonitis By Stage

• Tendonitis Assessment by Route of Administration

• Tendonitis Assessment by Molecule Type

Download Tendonitis Sample report to know in detail about the Tendonitis treatment market @ Tendonitis Therapeutic Assessment

Table of Content

1. Report Introduction

2. Executive Summary

3. Tendonitis Current Treatment Patterns

4. Tendonitis – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Tendonitis Late-Stage Products (Phase-III)

7. Tendonitis Mid-Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Tendonitis Discontinued Products

13. Tendonitis Product Profiles

14. Tendonitis Key Companies

15. Tendonitis Key Products

16. Dormant and Discontinued Products

17. Tendonitis Unmet Needs

18. Tendonitis Future Perspectives

19. Tendonitis Analyst Review

20. Appendix

21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Tendonitis Pipeline Reports Offerings

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Tendonitis Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis | Seikagaku Corporation, MetrioPharm, MiMedx, Zhejia

Cutaneous T-Cell Lymphoma Pipeline Drugs Report 2025: Key 25+ Companies and Breakthrough Therapies Shaping the Future Landscape

DelveInsight’s “Cutaneous T-cell lymphoma Pipeline Insight 2025” report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in the Cutaneous T-cell lymphoma pipeline landscape. It covers the Cutaneous T-Cell Lymphoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Cutaneous T-Cell Lymphoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Cutaneous T-Cell Lymphoma Treatment Landscape. Click here to read more @ Cutaneous T-Cell Lymphoma Pipeline Outlook

Key Takeaways from the Cutaneous T-Cell Lymphoma Pipeline Report

In August 2025, Dren Bio announced a Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor activity of DR-01 in adult patients with large granular lymphocytic leukemia or cytotoxic lymphomas.
In August 2025, Prescient Therapeutics Ltd conducted a phase 2 randomized study to evaluate the efficacy, safety, pharmacokinetics (PK) and pharmadynamics (PD), of PTX-100 monotherapy at 500 or 1000 mg/m2 in patients with relapsed/refractory Cutaneous T-Cell Lymphoma (CTCL).
DelveInsight’s Cutaneous T-Cell Lymphoma pipeline report depicts a robust space with 25+ active players working to develop 30+ pipeline therapies for Cutaneous T-Cell Lymphoma treatment.
The leading Cutaneous T-Cell Lymphoma Companies such as HyBryte, Resminostat, Mundipharma International, Shanghai Pharmaceuticals Holding, Moleculin Biotech, Inc., BeiGene, Mundipharma Research Limited, Jiangsu Simcere Biologics Co., Ltd, Teva Pharmaceuticals USA, Pfizer, Galderma R&D, Merck Sharp & Dohme LLC, Bio-Path Holdings, Inc., Kymera Therapeutics, Inc., Karyopharm Therapeutics Inc and others.
Promising Cutaneous T-Cell Lymphoma Pipeline Therapies such as E7777, CD11301 0.03%, Panobinostat, ONTAK (denileukin difitox, DAB389IL-2), Quisinostat, 12 mg, APO866, Enzastaurin, SGX301 (synthetic hypericin), Mogamulizumab, Romidepsin (depsipeptide, FK228), and others.

Stay informed about the cutting-edge advancements in Cutaneous T-Cell Lymphoma Treatments. Download for updates and be a part of the revolution in oncology care @ Cutaneous T-Cell Lymphoma Clinical Trials Assessment

Cutaneous T-cell lymphoma Emerging Drugs

HyBryte: Soligenix

HyBryte™ (synthetic hypericin or SGX301) is a novel, first-in-class, photodynamic therapy utilizing safe, visible light for activation. The active ingredient in HyBryte™ is synthetic hypericin, a potent photosensitizer that is topically applied to skin lesions that is taken up by the malignant T-cells, and then activated by visible light approximately 24 hours later. The use of visible light in the red-yellow spectrum has the advantage of penetrating more deeply into the skin (much more so than ultraviolet light) and therefore potentially treating deeper skin disease and thicker plaques and lesions. Synthetic hypericin sodium, the active ingredient in HyBryte™, has Orphan Drug designation in the United States for the treatment of T-cell lymphoma and CTCL and in Europe for CTCL. HyBryte™ has received Fast Track designation for the treatment of cutaneous t-cell lymphoma in the United States.

AFM13: Affimed GmbH

AFM-13 is under development for the treatment of refractory and relapsed Hodgkin lymphoma, CD30+ lymphoma such as transformed mycosis fungoides, peripheral and cutaneous T-cell lymphoma, large B-cell lymphoma, B-cell non-Hodgkin lymphoma, Hodgkin lymphoma combination with check point inhibitors and Hodgkin lymphoma combination with lenalidomide. The drug candidate is administered intravenously. AFM-13 is a bi-specific, tetravalent human antibody, it acts by targeting CD30/CD16A. The drug is currently in Phase II stage of its development for the treatment of Cutaneous T Cell Lymphoma.

ASTX660: Otsuka Pharmaceutical Co., Ltd

ASTX660 (Tolinapant) is a novel, orally administered, non-peptidomimetic antagonist of the cellular and X-linked inhibitors of apoptosis proteins (cIAP1/2 and XIAP). Inhibitors of apoptosis proteins (IAPs) are frequently overexpressed in tumor cells and contribute to tumor cell survival and chemo-resistance. By inhibiting IAPs, tolinapant promotes cell death. Tolinapant also acts via a newly described immunomodulatory mechanism, which works to enhance an anti-tumor immune response in T-cell lymphomas. The drug is in Phase I/II for the treatment of CTCL.

WUCART007: Wugen

WU-CART-007 is an allogeneic, off-the-shelf, fratricide-resistant CD7-targeted CAR-T cell therapy engineered to overcome the technological challenges of harnessing CAR-T cells to treat CD7+ hematological malignancies. Wugen is deploying CRISPR/Cas9 gene editing technology to delete CD7 and the T-cell receptor alpha constant (TRAC), preventing CAR-T cell fratricide and mitigating the risk of graft-versus-host-disease (GvHD). WU-CART-007 is manufactured using healthy donor-derived T-cells to eliminate the risk of malignant cell contamination historically observed in the autologous CAR-T setting. Currently, the drug is in Phase I stage of its clinical trial for the treatment of CTCL.

The Cutaneous T-Cell Lymphoma pipeline report provides insights into

The report provides detailed insights about companies that are developing therapies for the treatment of Cutaneous T-Cell Lymphoma with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Cutaneous T-Cell Lymphoma Treatment.
Cutaneous T-Cell Lymphoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Cutaneous T-Cell Lymphoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Cutaneous T-Cell Lymphoma market.

Get a detailed analysis of the latest innovations in the Cutaneous T-Cell Lymphoma pipeline. Explore DelveInsight’s expert-driven report today! @ Cutaneous T-Cell Lymphoma Unmet Needs

Cutaneous T-Cell Lymphoma Companies

HyBryte, Resminostat, Mundipharma International, Shanghai Pharmaceuticals Holding, Moleculin Biotech, Inc., BeiGene, Mundipharma Research Limited, Jiangsu Simcere Biologics Co., Ltd, Teva Pharmaceuticals USA, Pfizer, Galderma R&D, Merck Sharp & Dohme LLC, Bio-Path Holdings, Inc., Kymera Therapeutics, Inc., Karyopharm Therapeutics Inc and others.

Cutaneous T-cell lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral
Intravenous
Subcutaneous
Parenteral
Topical

Cutaneous T-Cell Lymphoma Products have been categorized under various Molecule types such as

Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy

Discover the latest advancements in Cutaneous T-Cell Lymphoma Treatment by visiting our website. Stay informed about how we’re transforming the future of oncology @ Cutaneous T-Cell Lymphoma Market Drivers and Barriers, and Future Perspectives

Scope of the Cutaneous T-Cell Lymphoma Pipeline Report

Coverage- Global
Cutaneous T-Cell Lymphoma Companies- HyBryte, Resminostat, Mundipharma International, Shanghai Pharmaceuticals Holding, Moleculin Biotech, Inc., BeiGene, Mundipharma Research Limited, Jiangsu Simcere Biologics Co., Ltd, Teva Pharmaceuticals USA, Pfizer, Galderma R&D, Merck Sharp & Dohme LLC, Bio-Path Holdings, Inc., Kymera Therapeutics, Inc., Karyopharm Therapeutics Inc and others.
Cutaneous T-Cell Lymphoma Pipeline Therapies- E7777, CD11301 0.03%, Panobinostat, ONTAK (denileukin difitox, DAB389IL-2), Quisinostat, 12 mg, APO866, Enzastaurin, SGX301 (synthetic hypericin), Mogamulizumab, Romidepsin (depsipeptide, FK228), and others.
Cutaneous T-Cell Lymphoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Cutaneous T-Cell Lymphoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Cutaneous T-Cell Lymphoma Pipeline on our website @ Cutaneous T-Cell Lymphoma Emerging Drugs and Companies

Table of Content

Introduction
Executive Summary
Cutaneous T-cell lymphoma: Overview
Pipeline Therapeutics
Therapeutic Assessment
Cutaneous T-cell lymphoma– DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Drug Name: Company Name
Mid Stage Products (Phase II)
AFM13: Affimed GmbH
Early Stage Products (Phase I)
WUCART007: Wugen
Preclinical Stage Products
Drug Name: Company Name
Inactive Products
Cutaneous T-cell lymphoma Key Companies
Cutaneous T-cell lymphoma Key Products
Cutaneous T-cell lymphoma- Unmet Needs
Cutaneous T-cell lymphoma- Market Drivers and Barriers
Cutaneous T-cell lymphoma- Future Perspectives and Conclusion
Cutaneous T-cell lymphoma Analyst Views
Cutaneous T-cell lymphoma Key Companies
Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/cutaneous-t-cell-lymphoma-ctcl-pipeline-insight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Cutaneous T-Cell Lymphoma Pipeline Drugs Report 2025: Key 25+ Companies and Breakthrough Therapies Shaping the Future Landscape

Chronic Kidney Disease Pipeline Outlook Report 2025: Key 75+ Companies and Breakthrough Therapies Shaping the Future Landscape

DelveInsight’s, “Chronic Kidney Disease Pipeline Insight 2025” report provides comprehensive insights about 75+ companies and 80+ pipeline drugs in the Chronic Kidney Disease pipeline landscape. It covers the Chronic Kidney Disease pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Chronic Kidney Disease pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Chronic Kidney Disease Research. Learn more about our innovative pipeline today! @ Chronic Kidney Disease Pipeline Outlook

Key Takeaways from the Chronic Kidney Disease Pipeline Report

In August 2025, Boehringer Ingelheim announced a study is open to adults with chronic kidney disease (CKD) that is at risk of getting worse. People who have taken a specific type of medication for kidney disease called SGLT2 inhibitor within 1 month before the study or have certain health conditions cannot take part in this study. The purpose of this study is to find out whether a medicine called vicadrostat, used in combination with another medicine called empagliflozin, works in people with chronic kidney disease.
In August 2025, Bayer announced a study of researchers will check the medical history and current medications of the participants. They will also perform a complete health check-up of all the participants. Researchers will take urine and blood samples from the participants at different time points to measure UACR and eGFR.
DelveInsight’s Chronic Kidney Disease pipeline report depicts a robust space with 75+ active players working to develop 80+ pipeline therapies for Chronic Kidney Disease treatment.
The leading Chronic Kidney Disease Companies such as AstraZeneca, Eli Lilly and Company, Shandong Suncadia Medicine, Boehringer Ingelheim, AdAlta, Alebund Pharmaceuticals, SCOHIA PHARMA, DiaMedica Therapeutics, Roche, MC2 Therapeutics, Allena Pharmaceuticals, Regulus Therapeutics, UnicoCell Biomed, Regeneron Pharmaceuticals and others.
Promising Chronic Kidney Disease Pipeline Therapies such as roxadustat, Monofer®, AZD5718, Dapagliflozin 10 mg, MEDI8367, AST-120, and others.

Stay informed about the cutting-edge advancements in Chronic Kidney Disease treatments. Download for updates and be a part of the revolution in care @ Chronic Kidney Disease Clinical Trials Assessment

Chronic Kidney Disease Emerging Drugs Profile

Baxdrostat : AstraZeneca

Baxdrostat, a highly potent inhibitor of aldosterone synthase, exhibits greater selectivity for aldosterone synthase compared to existing ASIs. Initial studies in cynomolgus monkeys demonstrated its ability to decrease aldosterone production, prompting further investigation in humans. The mechanism of action of baxdrostat involves inhibiting the enzyme aldosterone synthase, which is responsible for the final step in aldosterone biosynthesis. By selectively blocking this enzyme, baxdrostat reduces aldosterone levels, leading to decreased sodium reabsorption and fluid retention, ultimately lowering blood pressure. The drug is currently being evaluated in the Phase III stage of development for the treatment of patients with CKD.

Ziltivekimab: Novo Nordisk

Ziltivekimab is a proprietary anti-interleukin-6 ligand monoclonal antibody (anti-IL6 mAb), targeting residual inflammatory cardiovascular risk in patients living with advanced chronic kidney disease (CKD). Ziltivekimab is being developed a therapy intended to reduce the risk of major cardiovascular adverse events in chronic kidney disease (CKD) patients with atherosclerotic cardiovascular disease (ASCVD) and inflammation. Patients who are diagnosed with moderate to severe CKD and have ASCVD and inflammation are at risk for an adverse cardiovascular event at a high rate and there are no approved therapies to prevent this risk. The proinflammatory cytokine, interleukin-6 (IL-6) has been shown to be an independent, causal factor of ASCVD with evidence generated from human genetic studies and preclinical studies. The drug is being evaluated in the Phase III stage of development to treat patients with moderate to severe chronic kidney disease.

BI-685509: Boehringer Ingelheim

BI 685509 is a novel small soluble guanylate cyclase (sGC) molecule activator that exhibits an in vitro profile consistent with that of an sGC activator. BI 685509 reduced proteinuria and glomerulosclerosis in the ZSF1 rat, a model of diabetic kidney disease (DKD), and reduced tubulointerstitial fibrosis in a 7-day unilateral ureteral obstruction model in rats. Currently, the drug is being evaluated in the Phase II stage of its development for the treatment of Chronic Kidney Disease.

PXL770: Poxel SA

PXL770, a first-in-class direct adenosine monophosphate-activated protein kinase (AMPK) activator, is focused on the treatment of adrenoleukodystrophy (ALD) and autosomal dominant polycystic kidney disease (ADPKD). Currently, the drug is in the Phase I stage of Clinical trial evaluation for the treatment of Autosomal Dominant Polycystic Kidney Disease.

RGLS8429: Regulus Therapeutics

RGLS8429 is a novel, next-generation oligonucleotide for the treatment of ADPKD designed to inhibit miR-17 and to preferentially target the kidney. Administration of RGLS8429 has shown robust data in preclinical models, where clear improvements in kidney function, size, and other measures of disease severity have been demonstrated along with a superior pharmacologic profile in preclinical studies compared to Regulus’ first-generation compound. Currently, the drug is in Phase I for the treatment of Chronic Kidney Disease.

The Chronic Kidney Disease Pipeline Report Provides Insights into

The report provides detailed insights about companies that are developing therapies for the treatment of Chronic Kidney Disease with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Chronic Kidney Disease Treatment.
Chronic Kidney Disease Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Chronic Kidney Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Chronic Kidney Disease market

Learn more about Chronic Kidney Disease Drugs opportunities in our groundbreaking Chronic Kidney Disease Research and development projects @ Chronic Kidney Disease Unmet Needs

Chronic Kidney Disease Companies

AstraZeneca, Eli Lilly and Company, Shandong Suncadia Medicine, Boehringer Ingelheim, AdAlta, Alebund Pharmaceuticals, SCOHIA PHARMA, DiaMedica Therapeutics, Roche, MC2 Therapeutics, Allena Pharmaceuticals, Regulus Therapeutics, UnicoCell Biomed, Regeneron Pharmaceuticals and others.

Chronic Kidney Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral
Intravenous
Subcutaneous
Parenteral
Topical

Chronic Kidney Disease Products have been categorized under various Molecule types such as

Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy

Discover the latest advancements in Chronic Kidney Disease treatment by visiting our website. Stay informed about how we’re transforming the future of disease @ Chronic Kidney Disease Market Drivers and Barriers, and Future Perspectives

Scope of the Chronic Kidney Disease Pipeline Report

Coverage- Global
Chronic Kidney Disease Companies- AstraZeneca, Eli Lilly and Company, Shandong Suncadia Medicine, Boehringer Ingelheim, AdAlta, Alebund Pharmaceuticals, SCOHIA PHARMA, DiaMedica Therapeutics, Roche, MC2 Therapeutics, Allena Pharmaceuticals, Regulus Therapeutics, UnicoCell Biomed, Regeneron Pharmaceuticals and others.
Chronic Kidney Disease Pipeline Therapies- Roxadustat, Monofer®, AZD5718, Dapagliflozin 10 mg, MEDI8367, AST-120, and others.
Chronic Kidney Disease Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Chronic Kidney Disease Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Chronic Kidney Disease Pipeline on our website @ Chronic Kidney Disease Emerging Drugs and Companies

Table of Content

Introduction
Executive Summary
Chronic Kidney Disease: Overview
Pipeline Therapeutics
Therapeutic Assessment
Chronic Kidney Disease– DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Baxdrostat: AstraZeneca
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
BI-685509: Boehringer Ingelheim
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
RGLS8429: Regulus Therapeutics
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Drug name: Company name
Drug profiles in the detailed report…..
Inactive Products
Chronic Kidney Disease Key Companies
Chronic Kidney Disease Key Products
Chronic Kidney Disease- Unmet Needs
Chronic Kidney Disease- Market Drivers and Barriers
Chronic Kidney Disease- Future Perspectives and Conclusion
Chronic Kidney Disease Analyst Views
Chronic Kidney Disease Key Companies
Appendix

About Us

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Chronic Kidney Disease Pipeline Outlook Report 2025: Key 75+ Companies and Breakthrough Therapies Shaping the Future Landscape

Atopic Dermatitis Pipeline Outlook Report 2025: Key 100+ Companies and Breakthrough Therapies Shaping the Future Landscape

DelveInsight’s, “Atopic Dermatitis Pipeline Insight, 2025” report provides comprehensive insights about 100+ companies and 120+ pipeline drugs in Atopic Dermatitis pipeline landscape. It covers the Atopic Dermatitis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Atopic Dermatitis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Download our comprehensive report now to explore clinical-stage developments and strategic collaborations transforming the industry! @ Atopic Dermatitis Pipeline Outlook Report

Key Takeaways from the Atopic Dermatitis Pipeline Report

In August 2025, Alphyn Biologics announced a study aiming to enroll 72 participants across 10 sites in Australia. There are 2 cohorts: Cohort 1: Mild to moderate atopic dermatitis Cohort 2: Mild to moderate atopic dermatitis – with secondary skin infection. Once assigned to a cohort participants will be randomised into 1 of 2 Groups: Arm A: Zabalafin hydrogel or Arm B: vehicle (placebo). Randomisation will be 2:1 ratio. There is up to 2 weeks for screening and study treatment period of 16 weeks.
In August 2025, Incyte Corporation announced a study is to assess the efficacy and safety of ruxolitinib cream in children and adolescents (6 to
In August 2025, Inmagene LLC conducted a study to assess the efficacy and safety profile of various dose regimens of IMG-007 in adult participants with moderate-to-severe active atopic dermatitis (AD) up to 52 weeks.
DelveInsight’s Atopic Dermatitis pipeline report depicts a robust space with 100+ active players working to develop 120-+ pipeline therapies for Atopic Dermatitis treatment.
The leading Atopic Dermatitis Companies such as Vanda Pharmaceuticals, TechnoDerma Medicines, Asana BioSciences, Artax Biopharma, Corvus Pharmaceuticals, Yuhan, BioVersys, Rubedo Life Sciences, Innocare Pharma, Apogee Therapeutics, Celldex Therapeutics, Aclaris Therapeutics, Astria Therapeutics and others.
Promising Atopic Dermatitis Pipeline Therapies such as Baricitinib, Dupilumab, Lebrikizumab, si-544, Lebrikizumab, MEDI9929, Dupilumab, Midazolam, Omeprazole, Emollient, and others.

Learn how leading Atopic Dermatitis Companies are positioning themselves for success in the evolving pharmaceutical market—access the full report today!” @ Atopic Dermatitis Clinical Trials Assessment

Atopic Dermatitis Emerging Drugs

ICP-332: Innocare Pharma

ICP-332 is a potent and selective TYK2 inhibitor that is being developed for the treatment of various T-cell related autoimmune disorders, including atopic dermatitis (AD), vitiligo, inflammatory bowel disease, etc., with broad market prospects. As a non-receptor tyrosine kinase, TYK2 is a member of the JAK kinase family, which is an important kinase on the JAK-STAT signaling pathway and plays an important role in the pathogenesis of inflammatory diseases. Currently, the drug is in Phase III stage of its clinical trial for the treatment of Atopic Dermatitis.

APG777: Apogee Therapeutics

APG777 is a novel, subcutaneous half-life extended monoclonal antibody targeting IL-13 for the potential treatment of AD. In head-to-head preclinical studies, APG777 showed equivalent or better potency to lebrikizumab in the inhibition of IL-13 signaling. APG777 Phase 1 trial data out to 12 months demonstrated a half-life of 77 days, a consistent safety and favorable PD profile showing near complete inhibition of pSTAT6 for up to 12 months after a single administration and sustained TARC inhibition. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Atopic Dermatitis.

Barzolvolimab: Celldex Therapeutics

Barzolvolimab is a humanized monoclonal antibody that binds the receptor tyrosine kinase KIT with high specificity and potently inhibits its activity. KIT is expressed in a variety of cells, including mast cells, which mediate inflammatory responses such as hypersensitivity and allergic reactions. KIT signaling controls the differentiation, tissue recruitment, survival and activity of mast cells. In certain inflammatory diseases, such as chronic urticaria, mast cell activation plays a central role in the onset and progression of the disease. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Atopic Dermatitis.

ATI-2138: Aclaris Therapeutics

ATI-2138 is an investigational oral covalent inhibitor of ITK, and JAK3 for the potential treatment of T cell-mediated autoimmune diseases. The ITK/JAK3 compound interrupts T cell signaling through the combined inhibition of ITK/JAK3 pathways in lymphocytes. Aclaris is developing ATI-2138 as a potential treatment for T cell-mediated autoimmune diseases. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Atopic Dermatitis.

STAR-0310: Astria Therapeutics

STAR-0310 is a monoclonal antibody designed as an OX40 antagonist, currently in preclinical development by Astria Therapeutics for the treatment of atopic dermatitis (AD) and potentially other immunologic conditions. Its mechanism of action involves inhibiting the OX40 receptor, which plays a critical role in T cell activation and survival, thereby modulating immune responses associated with AD. STAR-0310 is characterized by its high affinity and potency, coupled with a significantly reduced antibody-dependent cellular cytotoxicity (ADCC), which may lead to a more favorable safety profile and a broader therapeutic window compared to existing therapies. Currently, the drug is in Phase I stage of its clinical trial for the treatment of Atopic Dermatitis.

The Atopic Dermatitis Pipeline report provides insights into

The report provides detailed insights about companies that are developing therapies for the treatment of Atopic Dermatitis with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Atopic Dermatitis Treatment.
Atopic Dermatitis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Atopic Dermatitis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Atopic Dermatitis market.

From early-stage research to late-phase Atopic Dermatitis Clinical Trials, our analysis covers key companies, innovative treatment approaches, and the next wave of Emerging Drugs. Don’t miss this opportunity to stay informed—download now! @ Atopic Dermatitis Treatment Drugs

Atopic Dermatitis Companies

Vanda Pharmaceuticals, TechnoDerma Medicines, Asana BioSciences, Artax Biopharma, Corvus Pharmaceuticals, Yuhan, BioVersys, Rubedo Life Sciences, Innocare Pharma, Apogee Therapeutics, Celldex Therapeutics, Aclaris Therapeutics, Astria Therapeutics and others.

Atopic Dermatitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral
Intravenous
Subcutaneous
Parenteral
Topical

Atopic Dermatitis Products have been categorized under various Molecule types such as

Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy

Stay updated with the latest Atopic Dermatitis Pipeline Insights—download our report for a deep dive into the next generation of therapeutics! @ Atopic Dermatitis Market Drivers and Barriers, and Future Perspectives

Scope of the Atopic Dermatitis Pipeline Report

Coverage- Global
Atopic Dermatitis Companies- Vanda Pharmaceuticals, TechnoDerma Medicines, Asana BioSciences, Artax Biopharma, Corvus Pharmaceuticals, Yuhan, BioVersys, Rubedo Life Sciences, Innocare Pharma, Apogee Therapeutics, Celldex Therapeutics, Aclaris Therapeutics, Astria Therapeutics and others.
Atopic Dermatitis Pipeline Therapies- Baricitinib, Dupilumab, Lebrikizumab, si-544, Lebrikizumab, MEDI9929, Dupilumab, Midazolam, Omeprazole, Emollient, and others.
Atopic Dermatitis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Atopic Dermatitis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Find answers in our latest Atopic Dermatitis Pipeline Insights report, featuring in-depth coverage of Clinical Trials, regulatory trends, and upcoming breakthroughs. Download now to stay at the forefront of pharmaceutical innovation!” @ Atopic Dermatitis Emerging Drugs and Companies

Table of Contents

Introduction
Executive Summary
Atopic Dermatitis: Overview
Pipeline Therapeutics
Therapeutic Assessment
Atopic Dermatitis– DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
ICP-332: Innocare Pharma
Mid Stage Products (Phase II)
APG777: Apogee Therapeutics
Early Stage Products (Phase I)
STAR-0310: Astria Therapeutics
Preclinical and Discovery Stage Products
Drug Name: Company Name
Inactive Products
Atopic Dermatitis Key Companies
Atopic Dermatitis Key Products
Atopic Dermatitis- Unmet Needs
Atopic Dermatitis- Market Drivers and Barriers
Atopic Dermatitis- Future Perspectives and Conclusion
Atopic Dermatitis Analyst Views
Atopic Dermatitis Key Companies
Appendix

About Us

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Atopic Dermatitis Pipeline Outlook Report 2025: Key 100+ Companies and Breakthrough Therapies Shaping the Future Landscape

Microbiome Disease Pipeline Outlook Report 2025: Key 140+ Companies and Breakthrough Therapies Shaping the Future Landscape

DelveInsight’s, “Microbiome Disease Pipeline Insights 2025” report provides comprehensive insights about 140+ companies and 180+ pipeline drugs in Microbiome Disease pipeline landscape. It covers the Microbiome Disease pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Microbiome Disease pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Download our comprehensive report now to explore clinical-stage developments and strategic collaborations transforming the industry! @ Microbiome Disease Pipeline Outlook Report

Key Takeaways from the Microbiome Disease Pipeline Report

In July 2025, Microbiome Health Sciences announced a study will be conducted as a multi-center, randomized, double-blind, placebo-controlled trial to evaluate the effect of MHS-1031 adjunctive to PPI therapy on heartburn-free days in subjects with GERD-related heartburn symptoms who self-report improvement while on sustained daily PPI therapy. Heartburn-free days will be determined by subject report specific to any of the three questions (“burning feeling behind the breastbone” and/or “pain behind your breastbone” and/or “heartburn”; Questions 1, 2 & 3 of the RESQ-eD).
DelveInsight’s Microbiome Disease pipeline report depicts a robust space with 140+ active players working to develop 180+ pipeline therapies for Microbiome Disease treatment.
The leading Microbiome Disease Companies such as MaaT Pharma, Qu Biologics, Biomica Ltd., Seres Therapeutics, Micro Viable Therapeutics, Metagen Therapeutics, Inc, Microbiotica, Enterome, Azitra, Vedanta Biosciences Inc. and others.
Promising Microbiome Disease Pipeline Therapies such as Omadacycline Injection, Imiquimod, Hydrocortisone Ointment, Clobetasol Ointment, Estrogen Cream, Altreno, Benzoyl peroxide, and others.

Learn how leading Microbiome Disease Companies are positioning themselves for success in the evolving pharmaceutical market—access the full report today!” @ Microbiome Disease Clinical Trials Assessment

Microbiome Disease Emerging Drugs Profile

MaaT 013: MaaT Pharma

MaaT013 is a standardized, high-richness, high-diversity Microbiome Ecosystem TherapyTM containing ButycoreTM (group of bacterial genera known to produce immuno-regulatory metabolites). It aims to restore the symbiotic relationship between the patient’s functional gut microbiome and their immune system to correct the responsiveness and tolerance of immune functions and reduce steroid-resistant, gastrointestinal-predominant aGvHD. MaaT013 has been granted Orphan Drug Designation by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA). MaaT013 is an off-the-shelf, healthy-multi-donors-derived product intended for acute, hospital use. Currently the drug is in Phase III stage of development for the treatment of Graft-versus-host disease.

QBKPN: Qu Biologics

QBKPN SSI, a first-in-class immune modulator designed to optimize immunity and barrier function in the lungs. The clinical trial is designed to assess QBKPN’s effectiveness in restoring innate immunity, the prevention of serious morbidity and mortality from respiratory infections, including COVID-19 and its variants, and reduction in all-cause mortality. QBKPN SSI is designed to restore and enhance innate immune function, the body’s first line of defense against all infections and other diseases such as cancer. Currently the drug is in Phase II stage of development for the treatment of immunodeficiency disorders.

BMC128: Biomica Ltd.

BMC128 is a rationally-designed microbial consortium identified and selected through a detailed functional microbiome analysis using PRISM, a proprietary high-resolution microbiome analysis platform powered by Evogene’s MicroBoost AI platform. Developed as a Live Bacterial Product (LBP), BMC128 is an LBP consortium comprised of four unique bacterial strains, natural inhabitants of the human intestinal tract, that harbour specific functional capabilities with the potential to enhance immunological therapeutic responses and facilitate anti-tumor immune activity through multiple biological processes. Rationally-designed consortia are multi-strain products designed to restore diversity and specific functionality to a host’s microbial community with individually selected, cultured bacteria. The drug is currently in Phase I stage of development for the treatment of patients with colorectal cancer.

SER-155: Seres Therapeutics

SER-155 is a consortium of bacterial species selected using Seres’ reverse translation discovery and development MbTx platform technologies. The design incorporates microbiome biomarker data from human clinical data and nonclinical human cell-based assays, and in vivo disease models. The SER-155 composition is designed to prevent and decrease the colonization and abundance of bacterial pathogens that can harbor antibiotic resistance and to enhance epithelial barrier integrity in the GI tract to both reduce the likelihood of pathogen translocation and decrease the incidence of bloodstream infections and GvHD. SER-155 has received FDA Fast Track Designation. The drug is currently in Phase I stage of development for the treatment of patients with Bacteraemia.

MVT-201: Micro Viable Therapeutics

MVT-201, is an orally administered capsule generated under cGMP conditions representing the complete gut microbiota of a clinically validated healthy donor and will get into the clinical trials in 2024 for undisclosed targets. The lead product, MVT-201, is under evaluation at pre-clinical stage with positive results, and it is a unique in its kind biological drug based on complete microbiota (HiPMTM) for undisclosed targets. The microbiota-derived product development platform also includes rationally design and defined bacterial consortia that will be advanced with this funding. This investment will enable to consolidate Microviable’s growth and focus towards the therapeutics, while increasing their facilities and headcount. The drug is currently in Preclinical stage of development for the treatment of patients with infectious diseases.

The Microbiome Disease Pipeline report provides insights into

The report provides detailed insights about companies that are developing therapies for the treatment of Microbiome Disease with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Microbiome Disease Treatment.
Microbiome Disease Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Microbiome Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Microbiome Disease market.

From early-stage research to late-phase Microbiome Disease Clinical Trials, our analysis covers key companies, innovative treatment approaches, and the next wave of Emerging Drugs. Don’t miss this opportunity to stay informed—download now! @ Microbiome Disease Treatment Drugs

Microbiome Disease Companies

MaaT Pharma, Qu Biologics, Biomica Ltd., Seres Therapeutics, Micro Viable Therapeutics, Metagen Therapeutics, Inc, Microbiotica, Enterome, Azitra, Vedanta Biosciences Inc. and others.

Microbiome Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intravenous
Subcutaneous
Oral
Intramuscular

Microbiome Disease Products have been categorized under various Molecule types such as

Monoclonal antibody
Small molecule
Peptide

Stay updated with the latest Microbiome Disease Pipeline Insights—download our report for a deep dive into the next generation of therapeutics! @ Microbiome Disease Market Drivers and Barriers, and Future Perspectives

Scope of the Microbiome Disease Pipeline Report

Coverage- Global
Microbiome Disease Companies- MaaT Pharma, Qu Biologics, Biomica Ltd., Seres Therapeutics, Micro Viable Therapeutics, Metagen Therapeutics, Inc, Microbiotica, Enterome, Azitra, Vedanta Biosciences Inc. and others.
Microbiome Disease Pipeline Therapies- Omadacycline Injection, Imiquimod, Hydrocortisone Ointment, Clobetasol Ointment, Estrogen Cream, Altreno, Benzoyl peroxide, and others.
Microbiome Disease Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Microbiome Disease Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Find answers in our latest Microbiome Disease Pipeline Insights report, featuring in-depth coverage of Clinical Trials, regulatory trends, and upcoming breakthroughs. Download now to stay at the forefront of pharmaceutical innovation!” @ Microbiome Disease Emerging Drugs and Companies

Table of Contents

Introduction
Executive Summary
Microbiome Disease: Overview
Pipeline Therapeutics
Therapeutic Assessment
Microbiome Disease– DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
MaaT 013: MaaT Pharma
Mid Stage Products (Phase II)
QBKPN: Qu Biologics
Early Stage Products (Phase I)
BMC128: Biomica Ltd.
Preclinical and Discovery Stage Products
MVT-201: Micro Viable Therapeutics
Inactive Products
Microbiome Disease Key Companies
Microbiome Disease Key Products
Microbiome Disease- Unmet Needs
Microbiome Disease- Market Drivers and Barriers
Microbiome Disease- Future Perspectives and Conclusion
Microbiome Disease Analyst Views
Microbiome Disease Key Companies
Appendix

About Us

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Microbiome Disease Pipeline Outlook Report 2025: Key 140+ Companies and Breakthrough Therapies Shaping the Future Landscape

ESCLC Pipeline Assessment Report 2025: Key 25+ Companies and Breakthrough Therapies Shaping the Future Landscape

DelveInsight’s, “Extensive-Stage Small Cell Lung Cancer (ESCLC) Pipeline Insight, 2025” report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in Extensive-Stage Small Cell Lung Cancer (ESCLC) pipeline landscape. It covers the ESCLC pipeline drug profiles, including clinical and nonclinical stage products. It also covers the ESCLC pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Download our comprehensive report now to explore clinical-stage developments and strategic collaborations transforming the industry! @ ESCLC Pipeline Outlook Report

Key Takeaways from the ESCLC Pipeline Report

In August 2025, Bristol-Myers Squibb announced a study is to Compare the Efficacy and Safety of BMS-986489 (Anti-fucosyl-GM1+ Nivolumab Fixed Dose Combination) in Combination with Carboplatin plus Etoposide to that of Atezolizumab with Carboplatin plus Etoposide as First-Line Therapy in Participants with Extensive-Stage Small Cell Lung Cancer.
In August 2025, Amgen conducted a study is to compare the efficacy of tarlatamab plus durvalumab with durvalumab alone on prolonging overall survival (OS).
In August 2025, BioNTech SE organized a Phase II study in participants with untreated extended-stage small-cell lung cancer (ES-SCLC) (Cohort 1) or small-cell lung cancer (SCLC) which has progressed on first- or second-line treatment (Cohort 2 and Cohort 3). This study will assess the safety, efficacy, and pharmacokinetics (PK) of BNT327.
DelveInsight’s ESCLC pipeline report depicts a robust space with 25+ active players working to develop 30+ pipeline therapies for ESCLC treatment.
The leading ESCLC Companies such as Shanghai Henlius Biotech, MacroGenics, Inc., RayzeBio, Inc., Genentech, Eli Lilly and Company, Amgen, Hutchison Medipharma Limited, Biocity Biopharmaceutics Co., Ltd., Biotheus Inc., GSK, InxMed (Shanghai) Co., Ltd., Daiichi Sankyo, Merck Sharp & Dohme LLC and others.
Promising ESCLC Pipeline Therapies such as LY2510924, Carboplatin, Etoposide, Talazoparib, Temozolomide, Durvalumab, Cisplatin, Vorolanib, Atezolizumab and others.

Learn how leading ESCLC Companies are positioning themselves for success in the evolving pharmaceutical market—access the full report today!” @ ESCLC Clinical Trials Assessment

ESCLC Emerging Drugs Profile

Serplulimab+Chemo: Shanghai Henlius Biotech

Serplulimab (anti-PD-1 mAb) in combination with chemotherapy can be used for the treatment of ESCC, ES-SCLC, and GC. The Phase III clinical studies of Serplulimab in combination with chemotherapy for the treatment of Neo/adj. GC and LS-SCLC are on the fast track. Phase III clinical studies for sqNSCLC, ES-SCLC and LS-SCLC are global multi-centre trials. Currently, the drug is in Phase III stage of its development for the treatment of Extensive-Stage Small Cell Lung Cancer (ESCLC).

Vobramitamab duocarmazine (MGC018): MacroGenics, Inc.

Vobramitamab duocarmazine (MGC018) is an investigational antibody-drug conjugate (ADC) comprised of a humanized B7-H3 monoclonal antibody (mAb) conjugated via a cleavable linker to the prodrug seco-DUocarmycin hydroxyBenzamide Azaindole (DUBA; licensed from Byondis, B.V.), with an average drug-to-antibody ratio (DAR) of ~2.7. DUBA is an alkylating agent that can damage DNA in both dividing and non-dividing cells, causing cell death. Vobra duo is designed to target solid tumors expressing B7-H3. Currently, the drug is in Phase II stage of its development for the treatment of Extensive-Stage Small Cell Lung Cancer (ESCLC).

RYZ101: RayzeBio, Inc.

RYZ101 is an investigational targeted radiopharmaceutical therapy, designed to deliver a highly potent radioisotope, Actinium-225 (Ac225), to tumors expressing the somatostatin receptor type 2 (SSTR2). RYZ101 is being evaluated in clinical studies for patients with SSTR+ gastroenteropancreatic neuroendocrine tumors who have previously been treated with Lu177-based somatostatin therapies and also in patients with extensive stage small cell lung cancer. RYZ101 is being combined with current standard of care therapy. Currently, the drug is in Phase I stage of its development for the treatment of of Extensive-Stage Small Cell Lung Cancer (ESCLC).

The ESCLC Pipeline report provides insights into

The report provides detailed insights about companies that are developing therapies for the treatment of ESCLC with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for ESCLC Treatment.
ESCLC Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
ESCLC Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the ESCLC market.

From early-stage research to late-phase ESCLC Clinical Trials, our analysis covers key companies, innovative treatment approaches, and the next wave of Emerging Drugs. Don’t miss this opportunity to stay informed—download now! @ ESCLC Treatment Drugs

ESCLC Companies

Shanghai Henlius Biotech, MacroGenics, Inc., RayzeBio, Inc., Genentech, Eli Lilly and Company, Amgen, Hutchison Medipharma Limited, Biocity Biopharmaceutics Co., Ltd., Biotheus Inc., GSK, InxMed (Shanghai) Co., Ltd., Daiichi Sankyo, Merck Sharp & Dohme LLC and others.

Extensive Stage Small Cell Lung Cancer (ESCLC) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral
Intravenous
Subcutaneous
Parenteral
Topical

ESCLC Products have been categorized under various Molecule types such as

Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy

Stay updated with the latest ESCLC Pipeline Insights—download our report for a deep dive into the next generation of therapeutics! @ ESCLC Market Drivers and Barriers, and Future Perspectives

Scope of the ESCLC Pipeline Report

Coverage- Global
ESCLC Companies- Shanghai Henlius Biotech, MacroGenics, Inc., RayzeBio, Inc., Genentech, Eli Lilly and Company, Amgen, Hutchison Medipharma Limited, Biocity Biopharmaceutics Co., Ltd., Biotheus Inc., GSK, InxMed (Shanghai) Co., Ltd., Daiichi Sankyo, Merck Sharp & Dohme LLC and others.
ESCLC Pipeline Therapies- LY2510924, Carboplatin, Etoposide, Talazoparib, Temozolomide, Durvalumab, Cisplatin, Vorolanib, Atezolizumab and others.
ESCLC Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
ESCLC Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Find answers in our latest ESCLC Pipeline Insights report, featuring in-depth coverage of Clinical Trials, regulatory trends, and upcoming breakthroughs. Download now to stay at the forefront of pharmaceutical innovation!” @ ESCLC Emerging Drugs and Companies

Table of Contents

Introduction
Executive Summary
Extensive Stage Small Cell Lung Cancer (ESCLC): Overview
Pipeline Therapeutics
Therapeutic Assessment
Extensive-Stage Small Cell Lung Cancer (ESCLC) – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Serplulimab+Chemo: Shanghai Henlius Biotech
Mid-Stage Products (Phase II)
Vobramitamab duocarmazine (MGC018): MacroGenics, Inc.
Early Stage Products (Phase I)
RYZ101: RayzeBio, Inc.
Preclinical and Discovery Stage Products
Drug Name: Company Name
Inactive Products
Extensive Stage Small Cell Lung Cancer (ESCLC) Key Companies
Extensive Stage Small Cell Lung Cancer (ESCLC) Key Products
Extensive Stage Small Cell Lung Cancer (ESCLC)- Unmet Needs
Extensive Stage Small Cell Lung Cancer (ESCLC)- Market Drivers and Barriers
Extensive Stage Small Cell Lung Cancer (ESCLC)- Future Perspectives and Conclusion
Extensive Stage Small Cell Lung Cancer (ESCLC) Analyst Views
Extensive Stage Small Cell Lung Cancer (ESCLC) Key Companies
Appendix

About Us

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: ESCLC Pipeline Assessment Report 2025: Key 25+ Companies and Breakthrough Therapies Shaping the Future Landscape

Sunshine Locksmiths; Trusted Locksmith, Shutter & Door Experts on the Costa del Sol

When it comes to the safety and security of your home or business, there’s no room for compromise. Whether you’re locked out, upgrading your property, or simply maintaining your peace of mind, Sunshine Locksmiths is the name you can trust across the Costa del Sol.

Based in Estepona and serving the areas of Marbella, San Pedro, Manilva, Casares, Cancelada, and Sotogrande, we offer fast, friendly, and reliable locksmith and security services with a personal touch.

Who We Are

Sunshine Locksmiths is more than just a locksmith service. We’re a local, family-run business with years of experience protecting homes and businesses in southern Spain. We take pride in being professional, transparent, and always on time.

Our goal is simple: to keep your property safe, secure, and stylish—whether it’s a cozy apartment in Marbella or a storefront in Estepona.

Our Services

We specialize in a wide range of services designed to make your life safer and easier:

24/7 Emergency Locksmith Services

Locked out of your home or car? Lost your keys? Don’t panic—we’re available day or night. Our emergency service is fast, affordable, and stress-free. We’ll get you back inside without damage or delay.

Door & Window Replacement

We supply and install high-quality doors and windows that are not only secure but also enhance your home’s appearance and insulation. Whether you’re renovating or replacing old fixtures, we offer modern, durable, and energy-efficient options.

Manual & Electric Shutters

From traditional manual shutters to modern electric and remote-controlled systems, we install and maintain shutters that protect your property from weather, noise, and break-ins. Great for both residential and commercial spaces.

Lock Upgrades & Installations

Old or weak locks can be a serious risk. We offer anti-bump, anti-drill, and high-security locks to give you the ultimate peace of mind. We also replace or rekey existing locks if you’ve moved in or lost keys.

Repairs & Maintenance

Something not working as it should? Our team can repair doors, shutters, locks, and windows, often on the same day. We don’t push for replacements unless it’s truly necessary—we’ll always try to fix it first.

Local, Reliable, and Honest

We live and work in the community. That means we understand the unique needs of properties in coastal areas—from salt air corrosion to seasonal rental security. Our business is built on trust, word of mouth, and real results.

With Sunshine Locksmiths, there are no hidden fees, no delays, and no excuses. Just honest work, great service, and fair prices.

Areas We Cover

We proudly serve:

Estepona

Marbella

San Pedro de Alcántara

Manilva

Casares

Cancelada

Sotogrande

And surrounding areas along the Costa del Sol.

If you’re unsure whether we cover your location, just give us a call — chances are we do!

Contact Us Today

Whether you need a fast locksmith, a shutter replacement, or a full security upgrade, Sunshine Locksmiths is here to help.

Email: sunshinelocksmithsinfo@gmail.com

Media Contact
Company Name: Sunshine Locksmiths
Contact Person: Press Office
Email: Send Email
Country: United States
Website: https://sunshinelocksmiths.es

New business class to Latin America; an elevated way to fly on over 80 selected routes

A’s new Business Class to Latin America transforms regional travel across over 80 selected routes throughout the Americas. It delivers an enhanced experience that reflects the airline’s commitment to elevated service and authentic Latin American hospitality, aiming to elevate the entire journey.

A seamless journey

The journey begins even before boarding, offering travelers a moment of calm to relax and prepare for their flight. Priority boarding ensures a smooth and stress-free transition onto the aircraft, while priority deplaning at the destination streamlines the arrival process. Every step is thoughtfully designed to elevate the travel experience and keep it flowing effortlessly.

Comfort and privacy onboard

Once aboard, passengers settle into seats designed for extended comfort, featuring extra space and enhanced recline to accommodate both work and rest during flight. The thoughtfully designed cabin layout provides privacy and room for business travelers, all while maintaining the warm, welcoming atmosphere Avianca is known for throughout the region. This elevated seating experience ensures refreshed arrivals.

A taste of Latin America

The culinary experience aboard Business Class to Latin America showcases a new onboard menu crafted by renowned chefs who draw inspiration from the rich gastronomic traditions of the region. Each dish tells a story of regional flavors, incorporating authentic ingredients and cooking techniques that celebrate the diverse culinary heritage found across the Americas. This approach to in-flight dining elevates meals into cultural experiences that connect passengers to their destinations.

Exclusive amenities

Complementing the elevated service is an exclusive amenity kit designed by Colombian designers, featuring carefully selected elements that highlight local craftsmanship and identity. This collaboration brings together regional creativity and premium wellness touches to create a kit that reflects both quality and cultural authenticity, providing passengers with essentials that enhance their journey. comfort throughout their journey. These carefully curated amenities further elevate comfort.

Extensive regional connectivity

The strength of Avianca’s regional route network becomes particularly evident through Business Class. The airline leverages its extensive connectivity to offer premium service on routes that matter most to travelers across the continent. This strategic network design ensures that business travelers can access major cities, emerging markets, and key destinations throughout the Americas while maintaining consistent service standards. The aim is to elevate access to essential destinations.

Beyond an upgrade

Business Class to Latin America represents more than an upgrade in seating or service; it embodies Avianca’s understanding of modern regional travel needs. By combining practical amenities like priority services and spacious seating with cultural elements such as regionally inspired cuisine and locally sourced amenity products, the airline creates an experience that honors both efficiency and the vibrant character of Latin American hospitality. This is how Avianca elevates the way one flies.

More information at: www.avianca.com/en/

Media Contact
Company Name: Avianca
Contact Person: Press Office
Email: Send Email
Country: United States
Website: https://www.avianca.com/en/

HR Positive/ HER2 Negative Breast Cancer Pipeline Outlook Report 2025: Key 50+ Companies and Breakthrough Therapies Shaping the Future Landscape

DelveInsight’s, “HR Positive/ HER2 Negative Breast Cancer Pipeline Insight, 2025,” report provides comprehensive insights about 50+ companies and 53+ pipeline drugs in HR Positive/ HER2 Negative Breast Cancer pipeline landscape. It covers the HR Positive/ HER2 Negative Breast Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the HR Positive/ HER2 Negative Breast Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Download our comprehensive report now to explore clinical-stage developments and strategic collaborations transforming the industry! @ HR Positive/ HER2 Negative Breast Cancer Pipeline Outlook Report

Key Takeaways from the HR Positive/ HER2 Negative Breast Cancer Pipeline Report

In August 2025, Puma Biotechnology, Inc. announced a Phase 2 study of alisertib administered in combination with endocrine therapy in participants with pathology-confirmed HR-positive/HER2-negative metastatic breast cancer (MBC) following progression on or after at least two prior lines of endocrine therapy in the recurrent or metastatic setting. This study is intended to evaluate the optimal alisertib dose administered in combination with the selected endocrine therapy. The study is also planned to evaluate the efficacy, safety, and pharmacokinetics of alisertib in combination with endocrine and to identify the biomarker-defined subgroup(s) that may benefit most from combined alisertib and endocrine therapy.
In August 2025, Merck Sharp & Dohme LLC conducted a Phase 3 study to Evaluate the Efficacy and Safety of Sac-TMT (Sacituzumab Tirumotecan, MK-2870) Followed by Carboplatin/Paclitaxel vs Chemotherapy, Both in Combination With Pembrolizumab as Neoadjuvant Therapy for High-Risk, Early-Stage, Triple-Negative Breast Cancer or Hormone Receptor-low Positive/Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer.
In August 2025, Relay Therapeutics, Inc. announced a Phase 3 study comparing the efficacy and safety of RLY-2608 + fulvestrant to capivasertib + fulvestrant for the treatment of patients with HR+/HER2- ABC with PIK3CA mutation following recurrence or progression on or after treatment with a CDK4/6 inhibitor.
DelveInsight’s HR Positive/ HER2 Negative Breast Cancer pipeline report depicts a robust space with 50+ active players working to develop 53+ pipeline therapies for HR Positive/ HER2 Negative Breast Cancer treatment.
The leading HR Positive/ HER2 Negative Breast Cancer Companies such as Regor Therapeutics, Seagen Inc., CytomX Therapeutics, Taizhou EOC Pharma, Chia Tai Tianqing Pharmaceutical Group, AstraZeneca, Daiichi Sankyo, Inc., Tyme, Inc., Context Therapeutics, Eisai Inc., Shanghai Hengrui Pharmaceutical Co., Ltd., Jiangsu Simcere Pharmaceutical Co., Kind Pharmaceuticals, Merus N.V., Atossa Therapeutics, Roche and others.
Promising HR Positive/ HER2 Negative Breast Cancer Pipeline Therapies such as TQB3616 capsule, Fulvestrant injection, Pembrolizumab, Sacituzumab Govitecan, VS-6766, Abemaciclib, Fulvestrant, Letrozole, Anastrozole, Exemestane and others.

Learn how leading HR Positive/ HER2 Negative Breast Cancer Companies are positioning themselves for success in the evolving pharmaceutical market—access the full report today!” @ HR Positive/ HER2 Negative Breast Cancer Clinical Trials Assessment

HR Positive/ HER2 Negative Breast Cancer Emerging Drugs Profile

Camizestrant: AstraZeneca

Camizestrant is a potent, next-generation oral SERD and pure ERα antagonist, that has demonstrated anti-cancer activity across a range of preclinical models, including those with ER-activating mutations. The asset has been shown to promising anti-tumour profile when administered alone or in combination with palbociclib and thus, the company is running a Phase III trial for the same.

Dato-DXd: Daiichi Sankyo, Inc.

Datopotamab deruxtecan (Dato-DXd) is an investigational currently in Phase III for HR-positive, HER2- negative breast cancer. It is a TROP2 directed antibody drug conjugate (ADC) designed using Daiichi Sankyo’s proprietary DXd ADC technology, datopotamab deruxtecan is one of the three lead ADCs in the oncology pipeline of Daiichi Sankyo, and one of the most advanced programs in AstraZeneca’s ADC scientific platform. Datopotamab deruxtecan is comprised of a humanized anti-TROP2 IgG1 monoclonal antibody, developed in collaboration with Sapporo Medical University, attached to a number of topoisomerase I inhibitor payloads, an exatecan derivative, via tetrapeptide-based cleavable linkers.

CX-2009: CytomX Therapeutics

CX-2009 is a Probody drug conjugate that consists of a humanized anti-CD166 monoclonal antibody conjugated to DM4, a potent microtubule inhibitor known to be active against multiple cancer types. It is currently being tested in Phase II trial in Advanced HR-Positive/HER2-Negative Breast Cancer and of Praluzatamab Ravtansine as Monotherapy and in Combination with Pacmilimab (CX-072) in Advanced Triple-Negative Breast Cancer.

RGT-419B: Regor Therapeutics

RGT-419B is a new generation of CDK inhibitor with an optimized kinase activity spectrum. The clinical development program of RGT-419B is designed to address the unmet medical needs of patients who are refractory or have relapsed after previous treatment, providing new opportunities to improve survival and quality of life for patients with advanced/metastatic breast cancer. It is currently being tested in Phase I trial in in subjects with Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative Advanced/Metastatic Breast Cancer.

The HR Positive/ HER2 Negative Breast Cancer Pipeline report provides insights into

The report provides detailed insights about companies that are developing therapies for the treatment of HR Positive/ HER2 Negative Breast Cancer with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for HR Positive/ HER2 Negative Breast Cancer Treatment.
HR Positive/ HER2 Negative Breast Cancer Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
HR Positive/ HER2 Negative Breast Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the HR Positive/ HER2 Negative Breast Cancer market.

From early-stage research to late-phase HR Positive/ HER2 Negative Breast Cancer Clinical Trials, our analysis covers key companies, innovative treatment approaches, and the next wave of Emerging Drugs. Don’t miss this opportunity to stay informed—download now! @ HR Positive/ HER2 Negative Breast Cancer Treatment Drugs

HR Positive/ HER2 Negative Breast Cancer Companies

Regor Therapeutics, Seagen Inc., CytomX Therapeutics, Taizhou EOC Pharma, Chia Tai Tianqing Pharmaceutical Group, AstraZeneca, Daiichi Sankyo, Inc., Tyme, Inc., Context Therapeutics, Eisai Inc., Shanghai Hengrui Pharmaceutical Co., Ltd., Jiangsu Simcere Pharmaceutical Co., Kind Pharmaceuticals, Merus N.V., Atossa Therapeutics, Roche and others.

HR Positive/ HER2 Negative Breast Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intra-articular
Intraocular
Intrathecal
Intravenous
Ophthalmic
Oral
Parenteral
Subcutaneous
Topical
Transdermal

HR Positive/ HER2 Negative Breast Cancer Products have been categorized under various Molecule types such as

Oligonucleotide
Peptide
Small molecule

Stay updated with the latest HR Positive/ HER2 Negative Breast Cancer Pipeline Insights—download our report for a deep dive into the next generation of therapeutics! @ HR Positive/ HER2 Negative Breast Cancer Market Drivers and Barriers, and Future Perspectives

Scope of the HR Positive/ HER2 Negative Breast Cancer Pipeline Report

Coverage- Global
HR Positive/ HER2 Negative Breast Cancer Companies- Regor Therapeutics, Seagen Inc., CytomX Therapeutics, Taizhou EOC Pharma, Chia Tai Tianqing Pharmaceutical Group, AstraZeneca, Daiichi Sankyo, Inc., Tyme, Inc., Context Therapeutics, Eisai Inc., Shanghai Hengrui Pharmaceutical Co., Ltd., Jiangsu Simcere Pharmaceutical Co., Kind Pharmaceuticals, Merus N.V., Atossa Therapeutics, Roche and others.
HR Positive/ HER2 Negative Breast Cancer Pipeline Therapies- TQB3616 capsule, Fulvestrant injection, Pembrolizumab, Sacituzumab Govitecan, VS-6766, Abemaciclib, Fulvestrant, Letrozole, Anastrozole, Exemestane and others.
HR Positive/ HER2 Negative Breast Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
HR Positive/ HER2 Negative Breast Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Find answers in our latest HR Positive/ HER2 Negative Breast Cancer Pipeline Insights report, featuring in-depth coverage of Clinical Trials, regulatory trends, and upcoming breakthroughs. Download now to stay at the forefront of pharmaceutical innovation!” @ HR Positive/ HER2 Negative Breast Cancer Emerging Drugs and Companies

Table of Contents

Introduction
Executive Summary
HR Positive/ HER2 Negative Breast Cancer: Overview
Pipeline Therapeutics
Therapeutic Assessment
HR Positive/ HER2 Negative Breast Cancer– DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Dato-DXd: Daiichi Sankyo, Inc.
Mid Stage Products (Phase II)
CX-2009: CytomX Therapeutics
Early Stage Products (Phase I)
RGT-419B: Regor Therapeutics
Preclinical and Discovery Stage Products
Drug Name: Company Name
Inactive Products
HR Positive/ HER2 Negative Breast Cancer- Unmet Needs
HR Positive/ HER2 Negative Breast Cancer- Market Drivers and Barriers
Appendix

About Us

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: HR Positive/ HER2 Negative Breast Cancer Pipeline Outlook Report 2025: Key 50+ Companies and Breakthrough Therapies Shaping the Future Landscape